Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay K Singh

Showing results (1-10 of 270) with videos related to

Pageof 27
Sort By:
Current Diabetes Reports|June 15, 2010
Diabetes, anemia and CKD: Why TREAT?Ajay K Singh
Current Opinion in Nephrology and Hypertension|August 7, 2010
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?Ajay K Singh
Journal of the American Society of Nephrology : JASN|December 26, 2009
Does TREAT give the boot to ESAs in the treatment of CKD anemia?Ajay K Singh
Nature Clinical Practice. Nephrology|October 18, 2007
Does correction of anemia slow the progression of chronic kidney disease?Ajay K Singh
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 26, 2008
The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?Ajay K Singh
Kidney International|September 1, 2011
Is there a deleterious effect of erythropoietin in end-stage renal disease?Ajay K Singh
Nature Reviews. Nephrology|September 26, 2012
Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?Ajay K Singh
NEJM Evidence|February 6, 2024
Dapafliglozin and Correction of Anemia in Patients with CKDAjay K Singh
Clinical Journal of the American Society of Nephrology : CJASN|August 7, 2010
Message to the FDA on ESAs: REMS is not enough, more studies are neededAjay K Singh
Nephrology News & Issues|May 24, 2007
The FDA black box for EPO: what should nephrologists do?Ajay K Singh
Pageof 27

Showing results (1-10 of 270) with videos related to

Sort By:
Pageof 27
Current Diabetes Reports|June 15, 2010
Diabetes, anemia and CKD: Why TREAT?Ajay K Singh
Current Opinion in Nephrology and Hypertension|August 7, 2010
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?Ajay K Singh
Journal of the American Society of Nephrology : JASN|December 26, 2009
Does TREAT give the boot to ESAs in the treatment of CKD anemia?Ajay K Singh
Nature Clinical Practice. Nephrology|October 18, 2007
Does correction of anemia slow the progression of chronic kidney disease?Ajay K Singh
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 26, 2008
The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?Ajay K Singh
Kidney International|September 1, 2011
Is there a deleterious effect of erythropoietin in end-stage renal disease?Ajay K Singh
Nature Reviews. Nephrology|September 26, 2012
Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?Ajay K Singh
NEJM Evidence|February 6, 2024
Dapafliglozin and Correction of Anemia in Patients with CKDAjay K Singh
Clinical Journal of the American Society of Nephrology : CJASN|August 7, 2010
Message to the FDA on ESAs: REMS is not enough, more studies are neededAjay K Singh
Nephrology News & Issues|May 24, 2007
The FDA black box for EPO: what should nephrologists do?Ajay K Singh
Pageof 27